ZYME Zymeworks

Zymeworks to Present at UBS Global Healthcare Conference

VANCOUVER, British Columbia--(BUSINESS WIRE)--

Zymeworks Inc. (“Zymeworks”) (NYSE:ZYME; TSX:ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced it will present at the 2017 UBS Global Healthcare Conference.

Conference Details:

Event:     UBS Global Healthcare Conference
Date/Time: May 23, 2017 at 11:30 a.m. EDT
Location: New York, NY

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. Zymeworks’ suite of complementary therapeutic platforms and its fully-integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly-differentiated product candidates. Zymeworks’ lead product candidate, ZW25, is a novel bispecific antibody currently being evaluated in an adaptive Phase 1 clinical trial. Zymeworks is also advancing a deep pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged through multiple strategic partnerships with global biopharmaceutical companies.

EN
12/05/2017

Underlying

ZYMEZymeworks

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zymeworks

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.72
EW EDWARDS LIFESCI...
GWRE GUIDEWIRE SOFTW... ... (+34)

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

EW EDWARDS LIFESCIENCES CORP
GWRE GUIDEWIRE SOFTWARE INC.
NOW SERVICENOW INC.
IZZ TAL EDUCATION GROUP SPONSORED ADR CLASS A
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SPLK SPLUNK INC.
PRLB PROTO LABS INC.
PRGO PERRIGO CO. PLC
PEGA PEGASYSTEMS INC.
PDFS PDF SOLUTIONS INC.
NSY NICE SYSTEMS LTD (ADR)
KURA KURA ONCOLOGY INC.
HRTX HERON THERAPEUTICS INC
EPZM EPIZYME INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
APPF APPFOLIO INC CLASS A
ADVM ADVERUM BIOTECHNOLOGIES
ADBE ADOBE INC.
AWK AMERICAN WATER WORKS COMPANY INC.
EA ELECTRONIC ARTS INC.
COUP COUPA SOFTWARE INC.
KNSL KINSALE CAPITAL GROUP INC.
NMI. KIRKLAND LAKE GOLD LTD.
ZYME ZYMEWORKS
GLPG GALAPAGOS NV
IOVA IOVANCE BIOTHERAPEUTICS INC
TNDM TANDEM DIABETES CARE
BAND BANDWIDTH CLASS A
CWEN CLEARWAY ENERGY INC. CLASS C
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
FOX FOX CORPORATION CLASS B
PLMR PALOMAR HOLDINGS
SGEN SEAGEN INC.
RIDE LORDSTOWN MOTORS CORP (A)
03/18/21 March 18, 2021 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.72
GEO GEO GROUP INC. ...
DEI Douglas Emmett ... ... (+38)

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

GEO GEO GROUP INC. (THE)
DEI DOUGLAS EMMETT INC
ADI ANALOG DEVICES INC.
WBA WALGREENS BOOTS ALLIANCE INC
TM.N TOYOTA MOTOR ADS
SMP STANDARD MOTOR PRODUCTS INC.
QURE UNIQURE NV
PPC PILGRIM'S PRIDE CORPORATION
PGRE PARAMOUNT GROUP INC.
OSIS OSI SYSTEMS INC.
NTRS NORTHERN TRUST CORPORATION
MRK MERCK & CO. INC.
MERC MERCER INTERNATIONAL INC.
MANT MANTECH INTERNATIONAL CORPORATION CLASS A
EQR EQUITY RESIDENTIAL
DDD 3D SYSTEMS CORPORATION
CVS CVS HEALTH CORPORATION
CFFN CAPITOL FEDERAL FINANCIAL INC.
CAJ CANON INC. ADS
BHE BENCHMARK ELECTRONICS INC.
BCO BRINK'S COMPANY
BAP. CREDICORP LTD.
AVB AVALONBAY COMMUNITIES INC.
AMBA AMBARELLA INC.
KRNY KEARNY FINANCIAL CORP.
46H HOLLYSYS AUTOMATION TECHNOLOGIES LTD.
NVS.. NOVARTIS AG ADS
PTI TELEKOMUNIKASI INDONESIA TBK PT (ADR)
ZYME ZYMEWORKS
AKCA AKCEA THERAPEUTICS INC.
KIDS ORTHOPEDIATRICS CORP
CI CIGNA CORPORATION
LEVI LEVI STRAUSS & CO. CLASS A
AIV APARTMENT INVESTMENT & MANAGEMENT CO CLASS A
APLT APPLIED THERAPEUTICS
SFL SFL CORPORATION LIMITED
TKPYY TAKEDA PHARMACEUTICAL CO. LTD. ADS
MSGE MADISON SQUARE GARDEN ENTERTAINMENT CORP.
07/23/20 July 23, 2020 21 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.72
WFC Wells Fargo & C...
VGR Vector Group Lt... ... (+45)

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

WFC WELLS FARGO & COMPANY
VGR VECTOR GROUP LTD.
STX SEAGATE TECHNOLOGY PLC
SSYS STRATASYS LTD.
SNP CHINA PETROLEUM & CHEMICAL CORP. ADS
ROST ROSS STORES INC.
OSIS OSI SYSTEMS INC.
ORA ORMAT TECHNOLOGIES INC.
NP NEENAH INC
MERC MERCER INTERNATIONAL INC.
MANUN MANCHESTER UNITED PLC
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LDOS LEIDOS HOLDINGS INC.
JWN NORDSTROM INC.
INTC INTEL CORPORATION
ESS ESSEX PROPERTY TRUST INC.
DUK DUKE ENERGY CORPORATION
DEA EASTERLY GOVERNMENT PROPERTIES INC
CSII CARDIOVASCULAR SYSTEMS INC.
K3PD CHINA MOBILE LTD.
CACI CACI INTERNATIONAL INC CLASS A
BWXT BWX TECHNOLOGIES INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
AVB AVALONBAY COMMUNITIES INC.
AMBA AMBARELLA INC.
AAT AMERICAN ASSETS TRUST INC.
NOC NORTHROP GRUMMAN CORPORATION
MHK MOHAWK INDUSTRIES INC.
FMX FOMENTO ECONOMICO MEXICANO S.A.B. DE C.V. ADS
PSXP PHILLIPS 66 PARTNERS LP
PTRN. PETROCHINA CO LTD
CNU. CNOOC LTD
PTI TELEKOMUNIKASI INDONESIA TBK PT (ADR)
ZYME ZYMEWORKS
AKCA AKCEA THERAPEUTICS INC.
MTEM MOLECULAR TEMPLATES
JBGS JBG SMITH PROPERTIES
NTR NUTRIEN LTD.
KRYS KRYSTAL BIOTECH INC
LEVI LEVI STRAUSS & CO. CLASS A
STNG SCORPIO TANKERS INC.
LHX L3HARRIS TECHNOLOGIES INC
HII. HORIZONS CDN INS
RTX RAYTHEON TECHNOLOGIES CORP.
NCGOF ABANCA CORPORACIÓN BANCARIA SA
07/16/20 July 16, 2020 24 EN
 PRESS RELEASE
Free
ZYME ZYMEWORKS

Zymeworks to Present at the 2017 American Society of Clinical Oncology...

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that it will be presenting Phase 1 clinical trial dose escalation data at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held from June 2-6, 2017 in Chicago, Illinois. The presentation will include detailed sa...

May 17, 2017 1 EN
 PRESS RELEASE
Free
ZYME ZYMEWORKS

Zymeworks Reports First Quarter 2017 Financial Results

VANCOUVER, British Columbia--(BUSINESS WIRE)-- Zymeworks Inc. (“Zymeworks”) (NYSE: ZYME; TSX: ZYME) a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today reported financial results for the first quarter ended March 31, 2017. “During the first quarter, among other highlights, we received top-line data from the dose escalation stage of our on-going Phase 1 clinical trial of o...

May 15, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch